

<https://helda.helsinki.fi>

Correction: Saarinen, N.V.V., et al. Multiplexed
High-Throughput Serological Assay for Human Enteroviruses.
Microorganismis 2020, 8, 963

Saarinen, Niila V. V.

Multidisciplinary Digital Publishing Institute
2020-09-17

Saarinen, N.V.V.; Lehtonen, J.; Veijola, R.; Lempainen, J.; Knip, M.; Hyöty, H.; Laitinen, O.H.; Hytönen, V.P. Correction: Saarinen, N.V.V., et al. Multiplexed High-Throughput Serological Assay for Human Enteroviruses. Microorganismis 2020, 8, 963. Microorganisms 2020, 8, 1426.

<http://hdl.handle.net/10138/348813>

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.



Correction

Correction: Saarinen, N.V.V., et al. Multiplexed High-Throughput Serological Assay for Human Enteroviruses. *Microorganisms* 2020, 8, 963

Niila V. V. Saarinen ¹, Jussi Lehtonen ¹, Riitta Veijola ², Johanna Lempainen ³, Mikael Knip ⁴, Heikki Hyöty ^{1,5}, Olli H. Laitinen ¹ and Vesa P. Hytönen ^{1,5,*}

¹ Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland; niila.saarinen@tuni.fi (N.V.V.S.); jussi.lehtonen@tuni.fi (J.L.); heikki.hyoty@tuni.fi (H.H.); olli.laitinen@tuni.fi (O.H.L.)

² Department of Paediatrics, University of Oulu, 90570 Oulu, Finland; riitta.veijola@oulu.fi

³ Department of Paediatrics, University of Turku, 20520 Turku, Finland; johanna.lempainen@utu.fi

⁴ Pediatric Research Center, Children’s Hospital, University of Helsinki and Helsinki University Hospital, and Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, 00029 Helsinki, Finland; mikael.knip@helsinki.fi

⁵ Fimlab Laboratories, 33520 Tampere, Finland

* Correspondence: vesa.hytonen@tuni.fi; Tel.: +358-401901517

Received: 10 September 2020; Accepted: 15 September 2020; Published: 17 September 2020



The authors wish to make the following correction to this paper [1]: The protein sequence corresponding to RV-A89 VP1 was erroneous in Table A2.

Table A2. Complete amino acid sequences of the recombinant VP1 antigens. VP1 parts unique to each antigen are typed in **bold**.

Antigen	Sequence
CVA4 VP1	MSPILGYWKIKGLVQPTRLLEYLEEKYEEHLYERDEGDKWRNKKFEL GLEFPNLPYYIDGDVKLQSMIIIRYIADKHNMLGGCPKERAISMLEG AVLDIRYGVSRVIAYSKDFETLKVDFLSKLPMLKMFEDRLCHKTYLNGD HVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIQIDKYLK SSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSGDAIADAIQNTVTST IQRVTNTVGGQDATAANTAPSSHSLNTGLVPALQAAETGASSTATD GNLIETRCVVNSNGTRETTHIEHFFSRSLVGVMEVDDTGTSGKGF NWDIDIMAFVQLRRKLEAFTYMRFDAEFTFVTNLENGLTNNSVIQY MYVPPGAPKPDARESFWQQTATNPSVFQKMDSPPPQVSVPFMSPAS AYQWFYDGYPTFGPHSETSNLSYGQCPNNMLGTFSARVVSKQITN QKFQIRIYLRKRVRAWIPRLRSQPYIYRNYPTYGTTIQYLAKDRR KITETDYNAEQR THPGHHHHHHHPG

Table A2. Cont.

Antigen	Sequence
CVB1 VP1	MSPILGYWKIKGLVQPTRLLEYLEEKYEEHLYERDEGDKWRNKKFELGLE FPNLPYYIDGDVKTQSMARIYIADKHNMLGGCPKERAISMLEGAVLDIR YGVSRAYSKDFETLKVDFLSKLPPEMLKMFEDRLCHKTYLNGDHVTHPDFM LYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIQIDKYLKSSKYIAWPLQG WQATFGGGDHPPKSDLVPRGSGPVEESVERAMVRVADTVSSKPTNSESI PALTAAETGHTSQVVPSDTMQTRHVKNYHSRSESSIENFLCRSACVYY ATYTNNSSKGYAEWVINTRQVAQLRRKLELFTYLRFDLELTFVITSAQQ PSTATSVDAVPQTHQIMYVPPGGPVPTKVTDYAWQTSTNPSVFWTEG NAPPRMSIPFISIGNAYSCFYDGTQFSRNGVYGINLNNMGTYLMRH VNEAGQGPIKSTVRIYFKPKHVKAWVPRPP RLCQYEKQKNVNFNPTGVTTRSNTITGAFPGHHHHHPG
PV1 VP1	MSPILGYWKIKGLVQPTRLLEYLEEKYEEHLYERDEGDKWRNKKFELGLE FPNLPYYIDGDVKTQSMARIYIADKHNMLGGCPKERAISMLEGAVLDI RYGVSRAYSKDFETLKVDFLSKLPPEMLKMFEDRLCHKTYLNGDHVTHPD FMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIQIDKYLKSSKYIAWPLQ GWQATFGGGDHPPKSDLVPRGSLGQMLSESMIDNTVRETVGAATSRDA LPNTEASGPAHSKEIPALTAJETGATNPLVPSDTVQTRHVQHRSRSESS IESFFARGACVAIITVDNSASTKNKDKLFTVWKITYKDTVQLRRKLEFFT YSRFDMEFTFVV TANFTETNNGHALNQVYQIMYVPPGAPVPEKWDDY TWQTSNPSIFITYGTAPARISVPYVGISNAYSHFYDGFVKVPLKQDSAA LGDSLYGAASLNDFGILAVRVVNDHNPTKVTSKIRVYLKPKHIRVWCPR PPRAVAYYGPVVDYKDGTLTPLSTKDLTTY GHHHHHPG
EV-D68 VP1	MSPILGYWKIKGLVQPTRLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEF PNLPPYYIDGDVKTQSMARIYIADKHNMLGGCPKERAISMLEGAVLDIR YGVSRAYSKDFETLKVDFLSKLPPEMLKMFEDRLCHKTYLNGDHVTHPDFML YDALDVVLYMDPMCLDAFPKLVCFKKRIEAIQIDKYLKSSKYIAWPLQG WQATFGGGDHPPKSDLVPRGSLDHLDAEAAAYQIESIIKTATDVTKSEISA ELGVVPSLNAVETGASSNTEPEEAIQTRTVINQHG VSETLVENFLSRAAL VSKRSFEYKNHTSSKARTDKNFFKWTINTKSFVQLRRKLELFTYLRFDA EITILTTAVANGSSNSTYMGLPDLTLQAMFVPTGALTPEKQDSFHWQSG SNASVFFKISDPPARM TIPFMCINSAYSVFYDGFAGFEKSGLYGINPADTI GNLCVRIVNEHQPIGFTVTVRVYMKPKHIKAWAPRPPRTL PYMSIANAN YRGKDRAPNALNAIIGNRESVKTMPHNI VTTPGHHHHHPG
RV-A89 VP1	MSPILGYWKIKGLVQPTRLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEF PNLPPYYIDGDVKTQSMARIYIADKHNMLGGCPKERAISMLEGAVLDIRY VSRAYSKDFETLKVDFLSKLPPEMLKMFEDRLCHKTYLNGDHVTHPDFM LYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIQIDKYLKSSKYIAWPLQGWQATF GGGDHPPKSDLVPRGS LDHLDAEAAAYQIESIIKTATDVTKSEISAELGVVPSLNAVETGASSNTEPEEAIQTR TVINQHG VSETLVENFLSRAALVSKRSFEYKNHTSSKARTDKNFFKWTINTKSFVQLR RKLELFTYLRFDAEITILTTAVANGSSNSTYMGLPDLTLQAMFVPTGALTPEKQDSFHW QSGSNASVFFKISDPPARM TIPFMCINSAYSVFYDGFAGFEKSGLYGINPADTIGNLCVR IVNEHQPIGFTVTVRVYMKPKHIKAWAPRPPRTL PYMSIANAN YRGKDRAPNALNAIIG NRESVKTMPHNIVTTPGHHHHHPG
RV-B14 VP1	MSPILGYWKIKGLVQPTRLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVK LTQSMARIYIADKHNMLGGCPKERAISMLEGAVLDIRYGVSRAYSKDFETLKVDFLSKLPPEML KMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIQIDKYL KSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSLGDELEEVIVEKTKQTVASISSGPKHTQK VPILTANETGATMPVLPDSIETRTTYMHFNGETDVECFLGRAACVHVTEIQNKDATGIDN HREAKLFNDWKINLSSLVQLRKKLELFTYVRFDSEYITLATASQPDSANYSSNLVVQAMVY PPGAPNPKEWDDYTWQSASNPSVFFKVGDTSRFSVPYVGLASAYNCFYDGYSHDDAETQ YGITVLNHMGSMFRIVNEHDEHKTLVKIRVYHRAKHV EAWIPRAPRALPYTSIGRTNYPKNTEPVIKRRKGDIKSYPGHHHHHPG
RV-C3 VP1	MSPILGYWKIKGLVQPTRLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVK LTQSMARIYIADKHNMLGGCPKERAISMLEGAVLDIRYGVSRAYSKDFETLKVDFLSKLPPEML KMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIQIDKYL KSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSPNVEEFVEHTLKEVLVVPDTQASGPVHTTK PQALGAVEIGATADVGPETLIETRYVMNDNTNAEAAVENFLGRSALWANLRLLDQGRKW EINFQEAHQVRKKFEMFTYVRFDEITIVTNNKGLMQIMFVPPGIPPGGDKGREWDTAS NPSVFFQPNSGFPRFTIPFTGLGSAYMYFDGYDGTDDANINYGISLTNDMGTLCFRALDG TGASDIKVFVKPKHITAWIPRPPRATQYLHKFSTNYNPKP TSGSTELEPKHFFKYRQDITSITNLPGHHHHHPG

To the correct version, as follows:

Table A2. Complete amino acid sequences of the recombinant VP1 antigens. VP1 parts unique to each antigen are typed in **bold**.

Antigen	Sequence
CVA4 VP1	MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDV VKLTQSMIIIRYIADKHNMLGGCPKERAIEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLP EMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPOI DKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSGDAIADAIQNTVTSTIQRVTTNTV GQDATAANTAPSSHSLNTGLVPALQAAETGASSTATDGNLIETRCVVNSNGTRETTHIEHF FSRSLVGVMEVDDTGTSGKGFNSWDIDIMAFVQLRRKLEAFTYMRFDAEFTFVNTLEN GLTNNSVIQYMYVPPGAPKPDARESFQWQTATNPSVQKMDSPPPQVSVPFMSPASAYQ WFYDGYPTFGPHSETSLSYGQCPNNMLGTF SARVVSQKITNQKFQIRIYRLRLKRVRAWI PRPLRSQPYIYRNYPTYGTTIQYLAKDRRKITETDYNAEQR THPGHHHHHHHPG
CVB1 VP1	MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDV LTQSMIIIRYIADKHNMLGGCPKERAIEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLP LKMFEEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPOIDK YLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSGPVEESVERAMVRVADTVSSKPTNSE SIPALTA AETGHTSQVVP SDTMQTRHVKNYHSRSESSIENFLCRSACVYATYTNNSKK G YAEWVINTRQVAQLRRKLELFTYLRFDLELTFVITSAQQPSTATSV DAPVQTHQIMYVP PGGPVPTKVTDYAWQSTNPSVFWTEGNAPPRMSIPFISIGNAYSFCYDGTWQFSRNGV YGINTLNNMGTLYMRHVNEAGQGQPIKSTVRIYFKPKHVKA WVP RPP RLCQYEKQKNVNFNPTGVTTRSNITTTGAFFGHHHHHHHPG
VP1 VP1	MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDV KLTQSMIIIRYIADKHNMLGGCPKERAIEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLP EMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPOI IDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSLDHLDAEAAEQIESIITATDTVKS RDALPNT EASGPAHSKEIPALTAVETGATNPLVPSDTVQTRHV VQHRSRSESSIESFFARG ACVAIITVDNSASTKNKDKLFTVWKITYKDTVQLRRKLEFFYSRFDMEFTFVVTANFTE TNNGHALNQVYQIMYVPPGAPVPEKWDDYTWTSSNPSIFYTYGTAPARISVPYVGISN AYSHFYDGFSGVPLKDQSAALGDSLYGAASLNDFGILAVRVVNDHNPTKVTSKIRVYLK PKHIRVWCPRPPRAVAYYGPV D YKDGTLTPLSTKDLTYP GHHHHHHHPG
EV-D68 VP1	MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDV LTQSMIIIRYIADKHNMLGGCPKERAIEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLP LKMFEEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPOIDK YLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSLDHLDAEAAEQIESIITATDTVKS EISAELGVVPSLNAVETGASSNTEPEEAIQTRTVINQHGVSETLVENFLSRAVSKRSFE YKNHTSSKARTDKNFFKWTINTKSFVQLRRKLELFTYLRFDAEITLTTVA VNGSSNSTYM GLPDLTLQAMFVPTGALTPEKQDSFHWQSGSNASVFFKISDPPARMTIPFMCINSAYSVF YDGFAGFEKSGLYGINP ADTIGNLCVRIVNEHQPIGFTVTVRVYMKPKHIKAWAPRPPRT LPYMSIANANYRGKDRAPNALNAIIGNRESVKTMPHNI VTTPGHHHHHHHPG
RV-A89 VP1	MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDV KLTQSMIIIRYIADKHNMLGGCPKERAIEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLP PEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAI POIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSGNPVENYIDSVLNEVLVVPNIQ PSTSVSSHAAPALDAAETGHTSSVQPEDMIETRYVITDQTRDETSIESFLGRSGCIAMIEF NTSSDKTEHDKIGKGFKTWVSLQEMAQIRRYELFTYTRFDSEITIVTAAAAQGNDSG HIVLQFMVYVPPGAPVPEKRDDYTWQSGTNASVFWQEGQPYPRFTIPFMSIASAYMYFYD G YDGD SAASKYGSVVTNDMG TICVRIVTSNQKHDSNIVCRIYHKAKHIKAWCPRPPRA VAYQHTSTNYIPSNGEATTQIKTRPDVFTVTNVG PSSMFP GHHHHHHHPG
RV-B14 VP1	MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDV LTQSMIIIRYIADKHNMLGGCPKERAIEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLP KMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPOIDK YLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSGLGDELEEVIVEKTKQTVASISSGPKHT QKVPILTANETGATMPVLP S DS IETRTTYMHFNGETDVECFLGRAACVHVTEIQNKDA TGIDNHREAKLFNDWKNLSSLVQLRKKLELFTYVRFDSEYITILATASQPDSANYSSNLVV QAMYPVPPGAPNPKEWDDYTWQ SASNPSVFFKVG DTSRFSVPYVGLASAYNCFYDGYSH DDAETQYGITVLNHMGSMFRIVNEHDEHKT LVKIRVYHRAKHV EAWIPRAPRALPYTSIGRTNYPKNTEPVIKRKGDIKSYPGHHHHHHHPG

Table A2. Cont.

Antigen	Sequence
RV-C3 VP1	MSPILGYWKIKGLVQPTRLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLT QSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSR IAYSKDFETLKVDFLSKLPEMLKM FEDRLCHKTYLNGDHSVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIQIDKYLKSSKY IAWPLQGWQATFGGGDHPPKSDLVPRGSDNPVEEFVEHTLKEVLVVPDTQASGPVHTTKPQALG AVEIGATADVGPETLIETRYVMNDNTNAEAAVENFLGRSALWANLRDQGF RKWEINFQEHA QVRKKFEMFTYVRFDEITIVTNNKGLMQIMFVPPGITPPGGKDGREWDTASNPSVFFQPNS GFPRFTIPFTGLGSAYYMFYDGYDGTDDANINYGISLTNDMGTLCFRALDGTGASDIKVF GK PKHITAWIPRPPRATQYLHKFSTNYNKPK TSGSTELEPKHFFKYRQDITSITNLPGHHHHHHPG

The authors would like to apologize for any inconvenience caused to the readers by this change.

Conflicts of Interest: H.H. and M.K. own stocks Vactech Ltd., which develops vaccines against picornaviruses. H.H. is the chairman of the Vactech board. H.H. and M.K. also serve on the scientific advisory board of Provention Bio Inc., which is developing an enterovirus vaccine. The other authors have no conflict of interest to declare. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Saarinen, N.V.V.; Lehtonen, J.; Veijola, R.; Lempainen, J.; Knip, M.; Hyöty, H.; Laitinen, O.H.; Hytönen, V.P. Multiplexed High-Throughput Serological Assay for Human Enteroviruses. *Microorganisms* **2020**, *8*, 963. [[CrossRef](#)] [[PubMed](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).